Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Goodwill & Intangibles (2023 - 2025)

Zevra Therapeutics' Goodwill & Intangibles history spans 3 years, with the latest figure at $11.1 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 84.91% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $11.1 million, down 84.91%, while the annual FY2025 figure was $11.1 million, 84.91% down from the prior year.
  • Goodwill & Intangibles reached $11.1 million in Q4 2025 per ZVRA's latest filing, down from $11.4 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $73.9 million in Q4 2023 to a low of $6.7 million in Q2 2024.
  • Average Goodwill & Intangibles over 3 years is $30.5 million, with a median of $11.4 million recorded in 2025.
  • The largest YoY upside for Goodwill & Intangibles was 75.43% in 2025 against a maximum downside of 90.75% in 2025.
  • A 3-year view of Goodwill & Intangibles shows it stood at $73.9 million in 2023, then dropped by 0.32% to $73.7 million in 2024, then plummeted by 84.91% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Goodwill & Intangibles are $11.1 million (Q4 2025), $11.4 million (Q3 2025), and $11.8 million (Q2 2025).